Glycation of high-density lipoprotein in type 2 diabetes mellitus

被引：7
作者：
Sun Jia-teng [1 ]
Shen Ying [2 ]
Lu An-kang [1 ]
Lu Lin [1 ]
Shen Wei-feng [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Sch Med, Dept Cardiol, Ruijin Hosp, Shanghai 200025, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Inst Cardiovasc Dis, Shanghai 200025, Peoples R China
来源：
CHINESE MEDICAL JOURNAL | 2013年 / 126卷 / 21期
关键词：
glycation; high-density lipoprotein; atherosclerosis; diabetes; APOLIPOPROTEIN-A-I; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; NONENZYMATIC GLYCATION; ANTIOXIDANT PROPERTIES; ENDOTHELIAL-CELLS; OXIDATIVE STRESS; ATHEROSCLEROSIS; IMPAIRS; HDL; DYSFUNCTION;
D O I：
10.3760/cma.j.issn.0366-6999.20131149
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Objective To evaluate whether glycation of high-density lipoprotein (HDL) increases cardiovascular risk in patients with type 2 diabetes mellitus by altering its anti-atherogenic property. Data sources Data cited in this review were obtained mainly from Pubmed and Medline in English from 2000 to 2013, with keywords "glycation", "HDL", and "atherosclerosis". Study selection Articles regarding glycation of HDL and its role in atherogenesis in both humans and experimental animal models were identified, retrieved and reviewed. Results Glycation alters the structure of HDL and its associated enzymes, resulting in an impairment of atheroprotective functionality and increased risks for cardiovascular events in type 2 diabetic patients. Conclusion Glycation of HDL exerts a deleterious effect on the development of cardiovascular complications in diabetes.
引用
收藏
页码：4162 / 4165
页数：4
相关论文
共 39 条
[1]   Effects of torcetrapib in patients at high risk for coronary events [J].
Barter, Philip J. ;
Caulfield, Mark ;
Eriksson, Mats ;
Grundy, Scott M. ;
Kastelein, John J. P. ;
Komajda, Michel ;
Lopez-Sendon, Jose ;
Mosca, Lori ;
Tardif, Jean-Claude ;
Waters, David D. ;
Shear, Charles L. ;
Revkin, James H. ;
Buhr, Kevin A. ;
Fisher, Marian R. ;
Tall, Alan R. ;
Brewer, Bryan .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2109-2122
[2]   Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy [J].
Boden, William E. ;
Probstfield, Jeffrey L. ;
Anderson, Todd ;
Chaitman, Bernard R. ;
Desvignes-Nickens, Patrice ;
Koprowicz, Kent ;
McBride, Ruth ;
Teo, Koon ;
Weintraub, William .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (24) :2255-2267
[3]   The Evolving Role of HDL in the Treatment of High-Risk Patients with Cardiovascular Disease [J].
Brewer, H. Bryan, Jr. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (05) :1246-1257
[4]   Small, dense HDL 3 particles attenuate apoptosis in endothelial cells: pivotal role of apolipoprotein A-I [J].
de Souza, Juliana A. ;
Vindis, Cecile ;
Negre-Salvayre, Anne ;
Rye, Kerry-Anne ;
Couturier, Martine ;
Therond, Patrice ;
Chantepie, Sandrine ;
Salvayre, Robert ;
Chapman, M. John ;
Kontush, Anatol .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2010, 14 (03) :608-620
[5]   An update on advanced glycation endproducts and atherosclerosis [J].
Del Turco, Serena ;
Basta, Giuseppina .
BIOFACTORS, 2012, 38 (04) :266-274
[6]   Dysfunctional high-density lipoprotein [J].
Feng, Hong ;
Li, Xiang-An .
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2009, 16 (02) :156-162
[7]   Structural modifications of HDL and functional consequences [J].
Ferretti, G ;
Bacchetti, T ;
Nègre-Salvayre, A ;
Salvayre, R ;
Dousset, N ;
Curatola, G .
ATHEROSCLEROSIS, 2006, 184 (01) :1-7
[8]   High-Density Lipoprotein Function, Dysfunction, and Reverse Cholesterol Transport [J].
Fisher, Edward A. ;
Feig, Jonathan E. ;
Hewing, Bernd ;
Hazen, Stanley L. ;
Smith, Jonathan D. .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2012, 32 (12) :2813-2820
[9]  
Gillery P, 2006, ANN BIOL CLIN-PARIS, V64, P309
[10]   Glycation impairs high-density lipoprotein function [J].
Hedrick, CC ;
Thorpe, SR ;
Fu, MX ;
Harper, CM ;
Yoo, J ;
Kim, SM ;
Wong, H ;
Peters, AL .
DIABETOLOGIA, 2000, 43 (03) :312-320
1234